MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Japan clears Abbott’s Mitraclip

Japan clears Abbott’s Mitraclip

By

Abbott's Mitraclip

Abbott (NYSE:ABT) said today it won approval from Japan’s Ministry of Health, Labour and Welfare for its MitraClip transcatheter mitral valve repair device, cleared for indications of treating people with mitral regurgitation.

Currently, standard of care treatment for mitral regurgitation in Japan is limited to open-heart surgery and medication, Abbott said. Clearance of the catheter-based MitraClip system adds a minimally-invasive treatment option not previously available in the region, the company added.

The MitraClip is designed to be delivered to the heart through a blood vessel in the leg, securing portions of the leaflets of the mitral valve with a clip to allow the heart to pump blood more efficiently through the body.

“It is our mission to help people suffering from structural heart disease return to better health and quality-of-life by providing technologies and therapies that advance how people are treated. With the approval of our revolutionary MitraClip device in Japan, we can help more people live better by reducing the severity of their extremely life-altering illness in a safe and predictable way,” structural heart biz VP Michael Dale said in a press release.

Approval in Japan came based on data from the AVJ-514 clinical trial in the region, which reported an 86.7% rate of 2+ or less mitral regurgitation and classified 96.7% of patients as NYHA class I or II with no major adverse events at 30 days.

“MitraClip provides a new treatment option for many people with severe mitral regurgitation who cannot undergo the mitral valve surgery. The introduction of MitraClip therapy in Japan will help more people who previously had limited options return to better health faster, with dramatically reduced symptoms,” trial principal investigator Dr. Kentaro Hayashida of Tokyo’s Keio University said in a press release.

Last week, Abbott said it won’t introduce its next-generation drug-eluting stent, the Xience Sierra, to the Indian market due to price caps there.

In case you missed it

RSS From Medical Design & Outsourcing

  • Baxter, 3M, Abbott near the top of Newsweek’s most responsible companies list
    Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with… […]
  • HHS reports 63-fold increase in telehealth use during pandemic
    A new study from the U.S. Department of Health and Human Services found a 63-fold increase in Medicare telehealth use during the COVID-19 pandemic. The report analyzed Medicare fee-for-service data from 2019 and 2020 and highlighted that people in urban areas were more likely to seek and use telehealth services than rural residents. In addition,… […]
  • Carlyle makes a significant investment in Resonetics
    Carlyle-managed funds have acquired a significant interest in medical device contract manufacturer Resonetics. Today’s announcement did not include the investment size, but the deal values Nashua, New Hampshire–based Resonetics at roughly  $2.25 billion. Carlyle joins existing investor GTCR as a meaningful shareholder in the company. Resonetics focuses on producing highly technical components for medical device… […]
  • Interpreting Pump Performance Curves
    Reading pump performance curves is crucial to proper pump selection. This piece reviews the creation and use of diaphragm pump performance curves to determine flow at given vacuum or pressure conditions. Included is a lesser-known method to interpolate pump performance when flow restrictions exist on both the inlet and outlet sides of the pump. Download… […]
  • BD elaborates on diversity and equity goals
    BD (NYSE:BDX) earlier this week outlined its efforts this year related to global inclusion, diversity and equity. Franklin Lakes, New Jersey-based BD released its 2021 Global Inclusion, Diversity and Equity (ID&E) Report, highlighting the progress it’s made in human health as part of its environmental, social and governance (ESG) strategy, according to a news release.… […]
  • How to protect medical devices from hidden cybersecurity risks
    Your software supply chain could be a cybersecurity risk. Here’s what you can do. Vince Arneja, GrammaTech The healthcare industry has been fighting a war on two fronts during the COVID-19 pandemic against the virus and an outbreak of cyberattacks. The Department of Health and Human Services says the sector reported a 9,851% increase in… […]
  • Integer completes $220M Oscor acquisition
    Integer Holdings (NYSE: ITGR) announced today that it has completed its purchase of Oscor — a deal that expands the capabilities of what was already one of the world’s largest medtech contract manufacturers. Integer said the acquisition would cost $220 million when it first announced its plans in October. Oscor is the creator and marketer… […]
  • Respira Labs seeks FDA clearance for its wearable lung monitor
    Respira Labs recently announced that it has developed a wearable device that continuously assesses lung function without the need for traditional pulmonary function tests. Mountain View, California-based Respira Labs designed its Sylvee wearable initially to assess chronic obstructive pulmonary disease, COVID-19 and asthma patients. It is embedded with speakers and microphones that measure the change… […]
  • Owen Mumford starts work on new production center in U.K.
    Owen Mumford this week announced that it has started building its new production facility in Witney, Oxfordshire in the U.K. Owen Mumford’s new Witney facility will stand as a production site for the company’s recently launched, next-generation auto-injector Aidaptus. The company has decades of experience creating its own drug delivery, blood sampling and rapid diagnostic… […]
  • FDA’s Woodcock reassures about COVID-19 tests, vaccines under Omicron
    Acting FDA Commissioner Dr. Janet Woodcock thinks many COVID-19 tests will continue to work with the new Omicron variant — with information coming soon on vaccine efficacy. In a statement posted yesterday, Woodcock said she thought the agency is well-positioned to work with companies to address the potential impact of viral mutations on COVID-19 tests,… […]
  • Traco Power launches THM 60WI DC-DC converters
    Traco Power today announced it has launched its THM 60WI series of quarter brick DC-DC converters. The Baar, Switzerlad-based company designed the DC-DC converters with ultra-wide input ranges and safety approvals for medical and industrial applications. Traco Power’s THM 60WI series of converters consists of 12 models with 9-75 or 18-75 Vin ranges with single… […]